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Abstract 
The antitumor prodrug Temozolomide is compromised by its dependence for activity on DNA mismatch 
repair (MMR) and the repair of the chemosensitive DNA lesion, O6-methylguanine (O6-MeG), by O6-
methylguanine-DNA-methyltransferase (EC 2.1.1.63, MGMT). Tumor response is also dependent on wild-
type p53. Novel 3-(2-anilinoethyl)-substituted imidazotetrazines are reported that  have activity 
independent of MGMT, MMR and p53. This is achieved through a switch of mechanism so that bioactivity 
derives from imidazotetrazine-generated arylaziridinium ions that principally modify guanine-N7 sites on 
DNA. Mono- and bi-functional analogs are reported and a quantitative structure-activity relationship 
(QSAR) study identified the p-tolyl-substituted bi-functional congener as optimized for potency, MGMT-
independence and MMR-independence. NCI60 data show the tumor cell response is distinct from other 
imidazotetrazines and DNA-guanine-N7 active agents such as nitrogen mustards and cisplatin. The new 
imidazotetrazine compounds are promising agents for further development and their improved in vitro 
activity validates the principles on which they were designed. 
 
Introduction 
The imidazotetrazine prodrug temozolomide 1 (TMZ), a DNA methylating agent, in combination with 
radiotherapy, is now first line treatment for glioblastoma multiforme (GBM) in North America and Europe. 
However, intrinsic and acquired resistance significantly limits the ultimate efficacy of therapy. In 
particular, tumor re-growth up to two years following TMZ treatment is aggressive and resistant to 
further TMZ therapy.1-3 This paper reports new compounds of the TMZ class that have activity 
independent of the two principal constraints on the ability of a tumor to respond to TMZ therapy: MGMT 
activity which directly repairs TMZ GO6-methylation of DNA, and MMR which enables the tumor response 
to TMZ therapy.2 
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Scheme 1.  The mechanism of action of temozolomide 1. 
 
At neutral pH, TMZ is relatively unstable (t1/2 = 1.24 h, pH 7.4)4 and undergoes hydrolytic ring-cleavage 
to the open chain triazene 5-(3-methyltriazen-1-yl)- imidazole-4-carboxamide (MTIC, t1/2 = 8 min, pH 7.4),5 
which then fragments to the highly reactive electrophile, methyldiazonium (t1/2 = 0.39 sec, pH 7.4).6-8 
Methyldiazonium reacts with nucleophilic groups on DNA, resulting in DNA methylation, Scheme 1. 
Approximately 70% of the methyl groups transferred to DNA appear at N7-guanine, 10 % at N3-adenine, 
and 5 % at O6-guanine sites. The N-methylation products are readily repaired by the base-excision repair 
pathways so are not major contributors to chemosensitivity.9 In contrast, O6-MeG lesions are reversed by 
direct removal by the MGMT protein. The MGMT gene is silenced by promoter methylation in 
approximately 35% of GBM.1 In these tumors, persistent O6-MeG lesions form wobble base-pairs with 
thymidine during replication; O6-MeG=T pairings result in futile cycles of mismatch repair, leading to 
stalled replication forks, DNA double-strand breaks and ultimately cell death.1 Low levels of MMR 
expression (or mutations leading to non-functional MMR) lead to a tolerant phenotype that cannot 
respond to TMZ. Consistent with these mechanisms of O6-MeG processing and repair, high-level 
expression of the MGMT protein is a major mechanism of inherent TMZ resistance in primary tumors. 
Down regulation or mutations of the MMR pathway or up-regulation of MGMT expression are important 
causes of acquired TMZ resistance in GBM.2 Herein we report the synthesis, pre-clinical activity in vitro 
and QSAR of new imidazotetrazines that have activity independent of MMR and MGMT. 
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Compound Design  
The imidazotetrazine bicycle is a prodrug of alkyldiazonium ions which are liberated by pH-dependent 
hydrolysis.6 Careful control of these reactive intermediates, in particular the suppression of competing 
side reactions, such as hydrolysis, elimination or re-arrangement,10-12 is essential in the design of effective 
new agents.13, 14 Furthermore, of the methyl groups transferred from TMZ to DNA, only a small fraction 
becomes the therapeutically-beneficial O6-MeG lesion: we sought to achieve therapeutic benefit though 
generation of N7-G-adducts, the major products of reaction of TMZ with DNA, thereby making more 
efficient use of the imidazotetrazine prodrug.  We have designed novel series of mono- (2a–i) and bi-
functional (3a–f) imidazotetrazines in which a 3-(2-anilinoethyl) group was substituted for the 3-methyl 
group of TMZ. The new compounds are efficient precursors of aziridinium ions, 4, Scheme 2. This strategy 
provides for effective control of the reactivity of incipient diazonium ions using a neighboring group 
participation mechanism not available to TMZ.  Moreover, aziridinium ions are reactive intermediates of 
proven clinical utility, being closely related to those generated by nitrogen mustard drugs, and are 
established as working through N7-guanine adducts.15 An additional feature of the drug design is the 
aniline para-substituent “X” of derivatives 2 and 3 that can be optimized to fine-tune pharmacological 
activity. This group affects the electron density at the aniline nitrogen by resonance or inductive effects 
and thereby controls the basicity and nucleophilicity of this site: i.e. the propensity either to protonate or 
to form an aziridinium ion. In addition, the bi-functional molecules would be expected to generate DNA 
cross-links, that would not be processed by MMR or MGMT and so avert those constraints on activity; 
previous studies have demonstrated that polar16 and bulky17 GO6 adducts cannot be processed by MGMT. 
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Scheme 2. Aziridinium ion formation by imidazotetrazine 2b.15 
Synthesis  
 
Scheme 3.  
The new imidazotetrazines were prepared by variants of the established TMZ synthesis where a 
diazoimidazole 5 is reacted with an isocyanate 6 to yield the imidazotetrazine, Scheme 3.18 The target 
compounds all included an aminoethyl group in the 3-position. The requisite β-aminoisocyanate 
precursors 7 are inherently unstable compounds as they bear incompatible functional groups. In the two 
aniline series, the anilines were sufficiently deactivated to allow isolation of the isocyanates without 
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recourse to protecting group strategies. The formation of the relatively fragile tetrazine ring was usually 
planned to be the last step in the synthesis. 
 
Scheme 4. Route to bis-imidazotetrazines 3. Reagents and conditions: (i) CuCl, AcOH, Δ, 76–98%; (ii) 
NH2NH2·xH2O, IPA, Δ, 64–99%; (iii) NaNO2, AcOH, H2O, CH2Cl2, 0 °C; (iv) PhMe, Δ, [>95%]; (v) DMSO, RT, 2 
d, 6–60% (over two steps) 
 
To prepare the dimers 3a–f, Cu(I)-catalyzed Aza-Michael conjugate addition of methyl acrylate to the 
requisite aniline furnished the diesters 8 in good (60–98%) yields, Scheme 4. Conversion to isocyanates 9 
was achieved through the intermediate hydrazides 10 and azides 11 followed by Curtius rearrangement. 
For the electron rich anilines (X=CH3, OMe), hydrazide formation had to be performed under very mildly 
acidic (0.17 M AcOH) conditions to avoid nitration of the aniline ring (10e → 11f → 3f). This is an 
attractive route as the bis-hydrazides are usually solids and easily purified while the Curtius 
rearrangement produces pure isocyanates directly, free from contaminating by-products.  
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Scheme 5 Route to mono-imidazotetrazines 2. Reagents and conditions: (i) CuCl, AcOH, Δ, 58–97%; (ii) 
NH2NH2·xH2O / IPA, Δ, 44–98%; (iii) NaNO2, AcOH, H2O, CH2Cl2, 0 °C; (iv) PhMe, Δ, [>95%]; (v) DMSO, RT, 
6–51% over two steps. 
 
The mono-imidazotetrazine analogs 2a–i were similarly prepared from N-methyl anilines, Scheme 5. In 
one example, the secondary aniline version 2g (R=H, X=Cl) was achieved using a BOC protection strategy 
that exploited the relative acid stability of the imidazotetrazine ring. Carefully controlled diazotization 
(12f → 13f → 14f) yielded BOC-protected isocyanatoethylaniline 15f; tetrazine ring closure followed by 
final treatment with TFA gave secondary aniline 2g. As a similar yield was obtained omitting the BOC 
group, the protection was shown to be redundant. The p-nitro derivative 2e was accessed from hydrazide 
13a by simultaneous diazotization and nitration under more vigorous conditions (10 M HCl); the mixture 
of regioisomers was carried through to the final step where the p-NO2 isomer, tetrazine 2e, was isolated 
by flash column chromatography. 
 
In vitro QSAR: influence of MGMT and MMR 
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Figure 1 . In vitro chemosensitivity (IC50 / µM) of new imidazotetrazine compounds against A2780 
(MMR+) and A2780-cp70 (MMR–) cell lines in the absence (MGMT+) and presence (MGMT–) of the MGMT 
inactivator PaTrin2 (10 µM). All data are the mean of ≥3 determinations, error bars are the SD; t-test 
analysis is presented in Table S3. * IC50 >250 µM. MEL, melphalan; CP, cisplatin. 
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Screening of all new compounds for chemosensitizing efficacy was undertaken following a protocol by 
Margisson et al that used the MGMT and MMR-proficient ovarian carcinoma cell line A2780, and its MMR-
deficient derivative A2780-cp70, Figure 1.19 To assess dependence of cytotoxicity on MGMT function, each 
cell line was further treated with the MGMT inactivator PaTrin2.20 The data are presented graphically in 
Figure 1 and fully tabulated in Table S1. As expected, sensitivity to TMZ and mitozolomide (MTZ) was 
highly dependent on both lack of MGMT activity and presence of wild-type MMR capacity. For TMZ, the 
IC50 was >250 µM in both A2780 and A2780-Cp70 cell lines, compared with IC50 = 8.5 and 231 µM 
respectively for the same cell lines co-treated with PaTrin2. In contrast, the novel imidazotetrazines were 
significantly more potent, with IC50 values in the A2780 wild-type line ranging from 22–73 µM for the 
mono-functional (2a–i) and 1–15 µM for the bi-functional (3a–f) compounds. Dependence on MMR can be 
examined by comparing the shaded bars with the grey bars (i.e. MMR+/MMR– with MGMT inactivated in 
both cases). For temozolomide the IC50 was >27–fold lower in the MMR-proficient cell line. For the new bi-
functional agents 3, this ratio was reduced to 5–5.8-fold and for the mono-functional agents 2, 2.8–10-fold. 
The extent of MGMT-mediated resistance can be assessed by comparing the shaded and the black bars (i.e. 
MGMT–/MGMT+ with MMR competent in both cases). Here, temozolomide was >30-fold more potent 
when MGMT was inactivated whilst for the new agents, this ratio was 0.5–5-fold for the bi-functional and 
1.1–2.9-fold for the mono-functional agents. Importantly, in the absence of MMR, all compounds showed 
activity greater than temozolomide irrespective of the MGMT status of the cells (white bars and grey bars) 
showing that MMR-dependent toxicity and MGMT-mediated resistance are now only minor determinants 
of the chemosensitizing effect. 
 
The similarity of response of examples 2d and 2g indicate that the N-methyl aniline is not essential to 
activity as the secondary and tertiary aniline compounds are equipotent (see Figure 1 and Table S1). 
Retention of the BOC group in analog 2f significantly reduced potency, presumably by impeding the 
aziridine/aziridinium formation step. Nitration in the aniline ring, whether as the sole or as an additional 
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substituent, resulted in reduced potency. This is consistent with electron withdrawal reducing 
nucleophilicity of the aniline and hence the propensity for aziridinium ion formation, (for examples, 
compare the compound pairs 3e/3f, 2a/2e, and 2b/2h). 
 
To probe the structure-activity relationship and examine MGMT and MMR dependence in more detail, 
the results for dimeric compounds 3a-e were presented in Hammett plots, Figure 2. The Hammett 
constant σ-p is a structural parameter that measures the electron donating or withdrawing effect of the 
substituent “X” on the aniline ring. The plot of IC50 against σ-p is informative in several respects, Figure 
2A. For each cell type, the graph shows a pair of lines, the dotted line being MGMT-inactivated data (i.e. 
PaTrin 2 present); the difference between the solid and dotted lines shows the effect of MGMT on the 
cellular response. For most analogs this separation is of the same order as the error bars on the data, so in 
effect is zero. This is a clear demonstration that these new compounds have activity independent of MGMT 
function and is consistent with a mechanism of action independent of guanine-O6 alkylation (or involving 
a guanine-O6 adduct that cannot be repaired by MGMT). The separation between the two pairs of lines is 
the MMR effect which ranges from about 2–5-fold on the IC50, which is greatly reduced from the >27-fold 
effect measured for TMZ. 
 
p-Methyl-substituted analog 3b lies on a minimum in the graph so is optimally potent, with a modestly 
electron-donating substituent on the aniline ring, Figure 2A. The data for all analogues except 3e (X = 
OMe) lie on exponential curves (see the semi-log plot, Figure 2B). The anomalous data for 3e are likely 
due to enhancement of the basicity of the aniline nitrogen lone pair leading to appreciable protonation at 
the pH of the experiment, and thereby a reduced propensity to act as a nucleophile in the aziridinium ion-
forming reaction. These data clearly demonstrate the direct effect of electron density at the aniline 
nitrogen in determining the in vitro activity of the compounds, so provide further evidence that the 
aziridinium ion mechanism occurs in cells. 
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Figure 2. (A, upper panel) Hammett plot of the IC50 data for the dimers 3a–e, in each case the MGMT– data 
are shown in dotted lines; the substituents X are shown in circles. (B, lower panel) QSAR Semi-log plot of 
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log IC50 vs. Hammett constant (σ-p) for the dimeric imidazotetrazines 3a–e. Regression lines were fitted 
omitting the data for OMe derivative 3e. 
NCI60 Panel Data  
Compounds 2d, and 3c-e were selected for full screening in the NCI 60 cell line panel. Mean graph data 
are presented in Figures S1–6 and are summarized in Table 1. These data show that the NCEs have 
pharmacological activity distinct from TMZ. TMZ is essentially inactive against the panel (GI50 > 10-4 M for 
57/60 cell lines, Figure S1). In contrast, the new agents exhibit strong patterns of discrimination over a 2–
3-log range of GI50 (Table 1 and Figures S2–5); this is important as it shows that the new compounds 
possess a degree of selectivity and are not uniformly cytotoxic against cells grown in culture.  These data 
compare favorably with the logGI50 mean and range data for established agents CHB, MEL, CP, BCNU and 
CCNU; this shows there is good reason to suppose that the new compounds may have an acceptable 
therapeutic index and be no more systemically toxic in vivo than these other clinically useful agents. 
 
 Log GI50  
Mean (SD) 
Log GI50 range 
2d –4.69 (0.58) 2.05 
3c –5.11 (0.69) 2.81 
3d –5.07 (0.52) 1.72 
3e –4.83 (0.46) 1.80 
MEL –4.54 (0.55) 1.88 
CHB –4.21 (0.56) 1.64 
CP –5.40 (1.10) 2.38 
BCNU –4.12 (0.82) 1.86 
CCNU –4.53 (0.48) 2.22 
 
Table 1 Summary of NCI60 statistics for compounds 2d, 3c–e, and established prodrugs for 
comparison. 
 
Particular sensitivity is evident in the leukemia, CNS and ovarian sub-panels.  In the CNS sub-panel, the 
pattern of activity is similar to MTZ and CP, with particular sensitivity in the glioblastoma lines SF295 and 
SNB75. In the ovarian sub panel, particular sensitivity is seen in the OVACR-3 and SK-OV-3 lines.  Here, in 
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contrast to the CNS activity, the new compounds show improvement over CP (see Figure S6) this is a 
particularly interesting result given the wide clinical use of CP against ovarian adenocarcinoma and the 
fact that TMZ lacks clinical activity against ovarian cancer.21 
 
COMPARE analysis of mean graph data can be valuable in discerning molecular mechanisms of action. 
The similarity in patterns of response is assessed by the Pearson rank correlation coefficient, P: values > 
0.7 are considered highly significant, values 0.6–0.7 less so.22, 23 Matrix COMPARE was valuable in 
confirming the novelty of mechanism of action of the new agents. In this method of data handling, the new 
compounds were compared with standard agents selected for similarities of chemical structure or 
predicted mechanism of action. Agents selected were other imidazotetrazines (TMZ, MTZ), nitrogen 
mustard cross linkers (chlorambucil CHB, melphalan MEL), nitrosoureas (1,3-Bis(2-chloroethyl)-1-
nitrosourea BCNU, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea CCNU) and CP, Table 2. Correlations amongst the four new imidazotetrazine compounds examined were all strong (0.92 ≤ P ≥ 0.77) and, 
interestingly, there was no clear discrimination between the mono- and bi-functional agents: for 
monofunctional 2d, 0.83 ≤ P ≥ 0.77 and in particular P = 0.79 with the equivalent p-Cl dimer 3d. Gratifyingly, the new compounds showed only moderate correlations (0.52 ≤ P ≥ 0.38) with the 
established imidazotetrazines TMZ and MTZ, so are distinct as new members of this compound class. The 
absence of correlation with MTZ is significant as this compound, exhibits a characteristic pattern of 
differential activity across the panel, unlike TMZ.  
 
The putative DNA lesion of the bifunctional agents 3 is a five-atom crosslink, related in structure to 
those formed by the nitrogen mustard prodrugs; however, no drugs of this class showed strong correlations 0.59 ≤ P ≥ 0.29. Notably, there was no similarity to the nitrosoureas which are also diazonium ion precursors, 0.45 ≤ P ≥ 0.05. The new compounds all showed strong correlations with dacarbazine 
(DTIC, highest dose = 1 µM).  This observation is not easy to interpret, as this prodrug requires hepatic 
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oxidative demethylation in order to release its active electrophile, so it is somewhat surprising that DTIC 
scored so highly against the new imidazotetrazines. Part of the reason for this may lie in the two relatively featureless datasets of DTIC [mean log GI50(SD) = –4.30(0.28), range = 0.99, high conc. = 104 M; mean log 
GI50(SD) = –3.66(0.548), range = 2.55, high conc. = 10–3 M] and a shared sensitivity in the leukemia sub-
panel. Simple COMPARE using DTIC GI50 (high conc. = 10-3 M) data as seed in the Standard Agents database yields no correlations P>0.537. 
 
 2d 3c 3d 3e TMZ MTZ DTIC MEL CHB BCNU CCNU CP 
2d 1 0.83 0.79 0.77 0.50 0.42 0.62 0.35 0.33 0.25 0.08 0.27 
3c 0.83 1 0.92 0.92 0.52 0.35 0.72 0.4 0.33 0.32 0.06 0.32 
3d 0.79 0.92 1 0.81 0.46 0.38 0.64 0.36 0.29 0.27 0.05 0.35 
3e 0.77 0.92 0.81 1 0.51 0.46 0.71 0.59 0.53 0.45 0.10 0.42 
Table 2. Results of Matrix COMPARE (P values) for NCEs 2d, 3c-e with selected standard agents.  
 
Simple COMPARE analysis was performed with the Standard Agents and Molecular Targets databases 
using the GI50 data as seed, Table 3. The Standard Agents data again identified similarity with DTIC, as 
noted above. In addition, modest correlations with 6MP and 6TG appeared for all four compounds, which 
is presumably linked to residual MMR-dependence,24, 25 a property that is shared with MTZ and DTIC. With 
the exception of compound 3e, correlations in the Molecular Targets database were not strong. Notable 
amongst the correlations of analog 3e are the lymphocyte and leukocyte related proteins LCP1, LRMP, 
RASSF5 and LAIR1 which may account for the high sensitivity of the leukemia sub-panel to these new 
compounds. Also intriguing are the correlations with the RAS-related proteins ARHGAP4 and RASSF5 and 
the moderate inverse correlation with RAB1A, a RAS superfamily GTPase.26  
 
All of the NCI cell lines are characterized for expression of MGMT and components of MMR.27 Plots of 
protein expression vs. log GI50 were prepared to probe correlation or inverse correlation between GI50 and 
 - 16 - 
expression of MGMT, hMLH1 (the core MMR protein) or MSH6 (the MMR domain that recognizes O6-
alkylG-DNA damage), see Figures S6-8. For each of the compounds 2d, 3c–e, the graphs showed scatters 
with no connection between the protein expression levels and GI50: a result consistent with the 
independence of activity from MGMT and MMR found in the A2780 cell line screen. 
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 Standard Agents Database  Molecular Targets Database 
 Pa 
DTICb 
P 
6TG 
P 
6MP 
 Strong positive correlationsc  
(P) 
Strongest negative correlation  
(P) 
2d 0.669 0.563 0.571  U2AF1 (0.61) RAB1A (–0.611) 
3c 0.751 0.543 0.524  RCSD1 (0.686) 
HCLS1 (0.683) 
RAB1A (–0.636) 
3d 0.717 0.515 0.527  WAS (0.526) RAB1A (–0.526) 
3e 0.727 0.573 0.515  HCLS1, WAS, NCKAP1L, LCP1, 
LRMP, ARHGAP4, RASSF5, CD53, LAIR1 (>0.7 for all) K1AA1191 (–0.64) RAB1A (–0.5136) 
TMZ       
MTZ 0.326 0.517 0.418    
       
aP, Pearson rank correlation coefficient;  bin all cases the highest ranking correlation was with DTIC; cexamples from the 10 top correlations, P 
values in parentheses. 6TG, 6-thioguanine; 6MP, 6-mercaptopurine; DTIC, dacarbazine. 
Table 3. Selected results from NCI60 screen and COMPARE analysis using the log GI50 data as seed in the Standard Agents and Molecular Targets 
databases. 
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Further in vitro evaluation 
The new compounds were further assessed in selected drug-resistant cell lines (Tables 4 and 5). 
HCT116 is a human colon carcinoma cell line that is deficient in both MGMT and MMR, in consequence 
it is insensitive to both TMZ and CP.28-30 Both mono- and bi-functional agent families showed 
considerably more potent activity than TMZ and MTZ in this cell line and, in further contrast, activity 
was retained in the p53-deficient mutant, Table 5. TMZ activity is known to be p53 dependent.31 
Compounds were also evaluated against an isogenic pair of SNB19 GBM cell lines competent in MMR 
that either expressed MGMT, SNB19(MGMT), or were negative for MGMT, SNB19(vector). This pair of 
cell lines highlights the improvements the new bi-functional agents offer over TMZ. The MGMT-
proficient line being remarkably insensitive to TMZ (IC50 is unattainable) and the new bi-functional 
agents showing equivalent activity against the two lines (IC50 6-12 µM) with increased potency against 
both SNB19(vector) and SNB19 (MGMT). A2058 is an aggressive melanoma line that is TMZ-sensitive 
and even so, the new bi-functional agents show a 10-fold increase in potency. 
 
 A2058 HCT116 SNB19(vector) SNB19(MGMT) 
2g >100 20.0 77.0 >100 
3c 5.5 12.5 11.0 12.0 
3e 2.5 5.5 6.6 7.0 
TMZ 35.5 >250 37.0 >250 
 
Table 4. IC50 (µM) for new compounds in selected TMZ-resistant cell lines using the Cyquant Assay 
(n=2).  
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 HCT116+/+a HCT116–/– a Ratio +/+: –/– 
2d 55 (8.2) 35.8 (7.1) 1.5 
2g 13.2 (14.1) 9.5 (4.8) 1.4 
3a 5.5 (1.2) 4.8 (2.1) 1.1 
3b 6.2 (n=2) 4.4 (2.7) 1.4 
3c 28 (8.1) 17 (5.3) 1.6 
3e 7.6 (2.1) 9.9 (n=2) 0.8 
MTZ 60 (11.2) 17.9 (8.9) 3.4 
CP 11.8 (n=2) 1.9 (2.5) 6.2 
Table 5. p53 Independence of chemosensitivity of HCT116 cell lines proficient and deficient in p53. 
IC50, µM (SD). a IC50 (µM) 
 
Discussion and Conclusions 
The aims of generating new imidazotetrazine prodrugs with activity independent of MGMT and 
MMR have been achieved through a rationally-designed switch in molecular mechanism. This 
complements other work, where alternative GO6-lesion dependent strategies have been pursued.29 
Two new families of mono- and bi-functional 3-anilinoethyl imidazotetrazines have been prepared. 
These were designed to shift the mechanism of action from dependence on GO6-DNA modification to 
GN7-modification. This was achieved through trapping the diazonium electrophile released on 
hydrolysis of the imidazotetrazine prodrug as an aziridinium ion. The mono-functional agent 2b is 
efficiently converted to an aziridinium ion (Scheme 2) and 2b and 3b are both DNA GN7-alkylators.15 
It is proposed, on the basis of analogy with reactive intermediates generated by nitrogen mustard and 
similar prodrugs, that biological activity is likely associated with this lesion.  However it is not yet 
possible to distinguish definitively between a mechanism of action deriving from GN7-adduct 
formation and one proceeding from GO6-adducts that are resistant to MGMT-mediated repair.  
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Screening in A2780 and A2780-cp70 cell lines showed that the new compounds are more potent 
than TMZ. The mono-functional agents are approximately equipotent with MTZ and the bi-functional 
agents more active. This activity is independent of MGMT activity as determined by use of the MGMT 
inactivator PaTrin2. Dependence of the IC50 on MMR is greatly reduced from approximately 30-fold for 
TMZ to 2–5-fold for the new bi-functional agents. The Hammett plot, Figure 2, for the bi-functional 
agents demonstrates the critical rôle of the para-substituent in directing the reactivity and bioactivity 
of the compounds, consistent with the aziridinium ion mechanism occurring in vitro and corroborating 
the design principles. The data identified the p-toluidine derivative 3b as the optimal analog for MGMT 
and MMR independence and potency. 
 
In the NCI60 screen, the new agents were not uniformly cytotoxic and showed distinct and 
individual patterns of response over a near 3-log range of GI50.  The patterns of biological response to 
the new agents were distinct from standard agents drawn from the imidazotetrazine, nitrogen 
mustard and nitrosourea families which, by chemical consideration, may be predicted to share similar 
mechanisms of action. For all compounds evaluated in the full 60 cell line screen, there was neither 
correlation with MLH1 or MSH6, nor inverse correlation with MGMT protein expression levels. 
Correlations in the Molecular Targets database suggest there may be a specific molecular mechanism 
that accounts for the sensitivity of the leukemia sub-panel to the new agents and, moreover, that 
activity could be linked to RAS family oncogenes. 
 
Collectively, the in vitro data show that the initial aims of improved potency and MGMT and MMR 
independence have been achieved. The switch of chemical mechanism has resulted in new agents that 
are distinct from existing imidazotetrazines, nitrogen mustards and nitrosoureas.  This  implies that an 
increased diversity of tumor types may now be able to respond to drugs of the imidazotetrazine class. 
NCI60 panel data identified CP-resistant ovarian carcinoma cell lines as responsive to the new agents. 
Chemosensitivity in selected drug-resistant colon carcinoma and glioma cell lines (HCT116 and 
SNB19) showed that there is activity against TMZ- and CP-resistant tumor lines of these types, and 
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moreover, that the HCT116 response is independent of p53 status.  The ability of cells to repair 
damage by the new agents is linked to the ATR and FANC pathways for the bi-functional and ATM and 
FANC pathways for mono-functional agents.32 Mutation in one of these genes would hypersensitize a 
tumour to these new agents. 
  
Overall these findings validate our understanding of the underlying chemistry of imidazotetrazine 
prodrugs. The members of our compound library are distinctive new agents, worthy of further 
development and application against a more diverse range of tumor types than TMZ. 
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Experimental  
Synthesis 
Reagents were purchased from Sigma-Aldrich, Alfa Aesar and Fluka, solvents from Fisher 
Scientific.  TLC was performed on highly-purified silica gel plates with UV indicator (silica gel F245), 
manufactured by Merck and visualized under UV light (366 or 254 nm) or stained with iodine. 
Melting points were determined with an Electrothermal IA9200 digital melting point apparatus. 
Infrared data were obtained using a Perkin Elmer (Paragon 1000) FT-IR Spectrophotometer. NMR 
spectra were acquired on a JEOL GX270 Delta, or where indicated ECA600, spectrometers 
observing 1H at 270.05 and 600.17 MHz and 13C at 67.80 and 150.91 MHz respectively. 13C 
assignments were made with the aid of the DEPT135 experiment. Mass spectra were obtained 
from the EPSRC National Mass Spectrometry Service Centre at the University of Swansea, UK, 
and the Analytical Centre at the University of Bradford using a Micromass Quattro Ultima mass 
spectrometer. Elemental analyses were obtained from the Advanced Chemical and Material 
Analysis Unit at the University of Newcastle upon Tyne, UK. All compounds entering biological 
evaluation were dried in vacuo for 3–4 days ≤35 °C ; ≥95% purity was adjudged by combustion 
analysis and hplc, solvation is indicated where appropriate; corresponding analytical hplc 
chromatograms and highfield 1H NMR spectra are shown in ESI. 
 
Compounds 2b and 3b were prepared as described in reference 15. 
 
Methyl 3-(4-chlorophenylamino)propanoate 12g 
General Method A: Single Conjugate Addition to Anilines. 
4-Chloroaniline (20.0 g, 157 mmol) was mixed with methyl acrylate (54.0 g, 627 mmol, 4 eq), 
cuprous chloride (1.56 g, 15.68 mmol, 0.1 eq) and AcOH (30 mL) and heated under reflux at 160 
°C for 2 h. The solvents were removed by evaporation and the residue partitioned between 
chloroform (500 mL) and water (500 mL). The organic layer was dried (MgSO4) in the presence of 
charcoal and filtered through celite. The solvents were removed leaving an oily residue. Petroleum 
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ether (200 mL) was added and heated to reflux. The solvent was decanted and the product 
precipitated upon standing. The solid was collected by filtration, washed with petroleum ether and 
dried to give the ester (23.7 g, 71 %): 1H NMR (CDCl3) 7.11 (d, J = 8.8 Hz, 2H, 2-H & 6-H), 6.55 (d, 
J = 8.8 Hz, 2H, 3-H & 5-H), 3.68 (OCH3), 3.41 (t, J = 7.2 Hz, 2H, CH2N), 2.61 (t, J = 7.2 Hz 2H, 
CH2CO); 13C NMR (CDCl3) 172.8 (C=O), 146.1 (C-1), 129.2 (C-2 & C-6), 122.5 (C-4), 114.3 (C-3 & 
C-5), 51.9 (OCH3), 39.7 (CH2N), 33.6 (CH2CO); MS (ES): m/z 214.1 (M+H)•+; IR (film) 3400, 1725, 
1600, 1500, 1435 cm-1. 
 
Methyl 3-(methyl(phenyl)amino)propanoate 12a15, 33  
Prepared by General Method A. Ester 12a was obtained as a colorless oil (13.3 g, 74 %). 1H 
NMR (CDCl3) 7.16 (t, 2H, J = 8.6 Hz, 3-H & 5-H), 6.64 (m, 3H, 2-H, 4-H & 6-H), 3.58 (m, 5H, CH2N 
& CH3N), 2.85 (s, 3H, OCH3), 2.49 (t, J = 7.3 Hz, 2H, CH2CO) 13C NMR (CDCl3) 172.8 (C=O), 
148.6 (C-1), 129.4 (C-3 & C-5), 116.9 (C-4), 112.6 (C-2 & C-6), 51.8 (OCH3), 48.7 (NCH2), 38.3 
(NCH3), 31.6 (CH2CO); MS (ES): m/z 194.1(M+H)•+; νmax (film) 1725s (C=O), 1175m (C-O) cm-1 
 
Methyl 3-((4-fluorophenyl)(methyl)amino)propanoate 12c 
Prepared according to General Method A. Ester 12c was obtained as an orange oil (2.22 g, 
75%). 1H NMR (CDCl3) 6.92 (m, 2H, 3-H & 5-H), 6.66 (m, 2H, m, 2-H & 6-H), 3.65 (s, 3H, OCH3), 
3.60 (t, J = 7.3 Hz, 2H, NCH2), 2.86 (NCH3), 2.52 (t, J = 7.3 Hz, 2H, CH2CO); 13C NMR (CDCl3) 
172.8 (C=O), 155.7 (d, 1JCF = 235 Hz, C-4), 145.5 (C-1), 115.7 (d, 2JCF = 22 Hz, C-3 & C-5), 114.1 
(d, 3JCF = 7 Hz, C-2 & C-6), 51.8 (CH3O), 49.5 (CH2N), 38.7 (CH3N), 31.5 (CH2CO); MS (ES): m/z 
212.1 (M+H)•+; IR (KBr) 3025m (Ar C-H), 2950m (C-H), 1725s (C=O), 1525m (Ar C=C), 1175m (C-
O) cm-1. 
 
Methyl 3-((4-chlorophenyl)(methyl)amino)propanoate 12d 
Prepared according to General Method A. Ester 12d was obtained as a yellow oil (9.1 g, 54%). 
1H NMR (CDCl3) 7.15 (d, J = 8.9 Hz, 2H, 3-H & 5-H), 6.63 (d, J = 8.9 Hz, 2H, 2-H & 6-H), 3.63 (s, 
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3H, OCH3), 3.62 (t, J = 7.2 Hz, 2H, NCH2), 2.89 (s, 3H, NCH3), 2.54 (t, J = 7.2 Hz, 2H, CH2CO); 13C 
NMR (CDCl3) 172.6 (C=O), 147.2 (C-1), 129.1 (C-3 & C-5), 121.7 (C-4), 113.9 (C-2 & C-6), 51.9 
(OCH3), 48.8 (NCH2), 38.4 (NCH3), 31.5 (CH2CO); MS (ES): m/z 228.1 (M+H)•+; IR (KBr) 3025m 
(Ar C-H), 2950m (C-H), 1725s (C=O), 1525m (Ar C=C), 1175m (C-O) cm-1. 
 
Methyl 3-((4-methoxyphenyl)(methyl)amino)propanoate 12e33 
According to General Method A. Ester 12e was obtained as a colorless oil (4.72 g, 58%): 1H 
NMR (CDCl3) 6.76 (d, 2H, J = 9.0 Hz, 3-H & 5-H), 6.67 (d, 2H, J = 9.0 Hz, 2-H & 6-H), 3.68 (s, 3H, 
CH3O-Ar), 3.59 (s, 3H, CH3OCO), 3.51 (t, J = 7.3 Hz, 2H, CH2N), 2.78 (s, 3H, CH3N), 2.46 (t, J = 
7.3 Hz, 2H, CH2CO); 13C NMR (CDCl3) 172.4 (C=O), 151.6 (C-4), 143.1 (C-1), 114.6 & 114.3 (C-3, 
C-5 & C2, C6), 55.3 (CH3O-Ar), 51.2 (CH3OCO), 49.4 (NCH2), 38.4 (CH3N), 30.9 (CH2CO); MS 
(ES): m/z 224.1 (M+H)•+; IR (film) 1725s (C=O), 1175m (C-O) cm-1. 
 
Methyl 3-(tert-butoxycarbonyl-(4-chlorophenyl)amino)propanoate 12f 
Ester 12g (2.27 g, 10.6 mmol) was mixed with di-tert-butyl carbonate (9.3 g, 42.6 mmol, 4 eq) in 
the absence of solvent. The mixture was heated at 100 °C for 18 h. The mixture was partitioned 
between H2O and petroleum ether. The organic phase was washed with H2O (5 x 50 mL), dried 
and evaporated to give ester 4h as an oil (3.2 g, 97%). 1H NMR (CDCl3) 7.29 (d, J = 8.8 Hz, 2H, 2-
H & 6-H), 7.11 (d, J = 8.8 Hz, 2H, 3-H & 5-H), 3.91 (t, J = 7.2 Hz, 2H, NCH2), 3.53 (OCH3), 2.57 (t, 
J = 7.2 Hz, 2H, CH2CO), 1.41 (s, 9H, C(CH3)3); 13C NMR (CDCl3) 172.3 (OC=O), 154.4 (NC=O), 
141.0 (C-1), 130.9 (C-4), 129.1 (C-2 & C-6), 113.7 (C-3 & C-5), 79.8 (C(CH3)3), 51.8 (OCH3), 48.2 
(NCH2), 32.8 (CH2CO), 28.4 (CH3); MS (ES): m/z 314.1 (M+H)•+; IR (film) 1725s (C=O), 1175m (C-
O) cm-1. 
 
3-(4-Chlorophenylamino)propanehydrazide 13g34, 35 
General Method B: Preparation of monohydrazides. 
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Ester 12g (3.7 g, 11.8 mmol, 1 eq) was mixed with hydrazine hydrate (5.9 g, 118 mmol, 10 eq) in 
propan-2-ol (10 mL) for 48h at RT. The volatiles were removed with evaporation to leave hydrazide 
13g as colorless oil (3.5 g, 95%). 1H NMR (DMSO-d6) 9.03 (br s, 1H, NHNH2), 7.05 (d, 2H, J = 8.9 
Hz, 2-H & 6-H), 6.53 (d, 2H, J = 8.8 Hz, 3-H & 5-H), 5.76 (br s, 1H, NH-aniline), 4.28 (s, br, 2H, 
NH2), 3.19 (t, J = 7.2 Hz, 2H, NCH2), 2.41 (t, J = 7.2 Hz, 2H, CH2CO); 13C NMR (DMSO-d6) 170.5 
(C=O), 148.0 (C-1), 129.1 (C-3 & C-5), 119.4 (C-4), 113.9 (C-2 & C-6), 39.9 (CH2N), 33.7 
(CH2CO); MS (ES): m/z 214.1 (M+H)•+; IR (KBr) 3300s (NH), 3050m (Ar C-H), 1650s (CONH) cm-1. 
 
3-(Methyl(phenyl)amino)propanehydrazide 13a 
Prepared according to General Method B. Hydrazide 13a was obtained as a colorless oil (12.7 g, 
98%). 1H NMR (CDCl3) 7.94 (br s, 1H, NH), 7.20 (t, 2H, J = 7.8 Hz, 3-H & 5-H), 6.69 (m, 3H, 2-H, 
4-H, 6-H), 3.62 (br, 4H, CH2N & NH2), 2.86 (s, 3H, CH3N), 2.33 (t, J = 6.8 Hz, 2H, CH2CO); 13C 
NMR (CDCl3) 172.5 (C=O), 148.7 (C-1), 129.4 (C-3 & C-5), 117.1 (C-4), 112.8 (C-2 & C-6), 49.2 
(NCH2), 38.6 (NCH3), 31.9 (CH2CO); MS (ES): m/z 194.1 (M+H)•+; IR (KBr) 3300s (NH), 3050m (Ar 
C-H), 1650s (CONH) cm-1. 
 
3-((4-Fluorophenyl)(methyl)amino)propanehydrazide 13c 
Prepared according to General Method B. Hydrazide 13c was obtained as a yellow oil (2.16 g, 
97%): 1H NMR (CDCl3) 7.47 (br s, 1H, NH), 6.91 (m, 2H, 3-H & 5-H), 6.66 (m, 2H, 2-H & 6-H), 3.56 
(t, J = 6.8 Hz, 2H, CH2N), 3.5 (br s, 2H, NH2), 2.83 (s, 3H, NCH3), 2.34 (t, J = 6.8 Hz, 2H, CH2CO); 
13C NMR (CDCl3) 172.4 (C=O), 156.0 (d, 1JCF = 237 Hz, C-4), 145.6 (C-1), 115.8 (d, 2JCF = 22 Hz, 
C-3 & C-5), 114.8 (d, 3JCF = 8 Hz, C-2 & C-6), 50.1 (CH2N), 39.3 (CH3N), 31.8 (CH2CO); MS (EI): 
m/z 212.1 (M+H)•+; IR (KBr) 3300m (NH), 3050m (Ar C-H), 1650s (CONH), 1525m (Ar C=C) cm-1. 
 
3-((4-Chlorophenyl)(methyl)amino)propanehydrazide 13d 
Prepared according to General Method B. Hydrazide 13d was obtained as white solid (4.0 g, 
44%): 1H NMR (CDCl3) 7.15 (d, 2H, J = 8.9 Hz, 3-H & 5-H), 7.03 (s, 1H, NH), 6.62 (d, 2H, J = 8.9 
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Hz, 2-H & 6-H), 3.86 (br s, 2H, NH2), 3.63 (t, J = 6.8 Hz, 2H, CH2N), 2.88 (s, 3H, NCH3), 2.35 (t, J = 
6.8 Hz, 2H, CH2CO); 13C NMR (CDCl3) 172.2 (C=O), 147.3 (C-1), 129.2 (C-3 & C-5), 122.1 (C-4), 
114.0 (C-2 & C-6), 49.3 (NCH2), 38.8 (NCH3), 31.8 (CH2CO); MS (ES): m/z 226.9 (M+H)•+; IR (KBr) 
3300m (NH), 3050m (Ar C-H), 1650s (CONH), 1525m (Ar C=C) cm-1. 
 
 
3-((4-Methoxyphenyl)(methyl)amino)propanehydrazide 13e  
Prepared according to General Method B. Hydrazide 13e was obtained as an oil which 
crystallized upon standing (4.5 g, 95%): 1H NMR (CDCl3) 7.63 (br s, 1H, NH), 6.80 (d, 2H, J = 9.2 
Hz, 3-H & 5-H), 6.75 (d, 2H, J = 9.2 Hz, 2-H & 6-H), 3.72 (s, 3H, CH3O-Ar), 3.47 (t, J = 6.6 Hz, 2H, 
CH2N), 3.3 (br s, 2H, NH2), 2.79 (s, 3H, NCH3), 2.33 (t, J = 6.6 Hz, 2H, CH2CO); 13C NMR (CDCl3) 
172.7 (C=O), 152.9 (C-4), 143.7 (C-1), 116.5 (C-2 & C-6), 114.9 (C-3 & C-5), 55.8 (CH3O-Ar), 50.7 
(CH2N), 40.0 (NCH3), 31.9 (CH2CO); MS (ES): m/z 224.1 (M+H)•+; IR (KBr) 3300s (NH), 3050m (Ar 
C-H), 1650s (CONH) cm-1. 
 
tert-Butyl-4-chlorophenyl(3-hydrazinyl-3-oxopropyl)carbamate 13f 
Prepared according to General Method B. Hydrazide 13f was obtained as a colorless oil (3.5 g, 
95%). 1H NMR (CDCl3) 7.76 (br s, 1H, NH), 7.22 (d, 2H, J = 7.8 Hz, 2-H & 6-H), 7.04 (d, 2H, J = 
7.8 Hz, 3-H & 5-H), 3.86 (t, J = 6.8 Hz, 2H, NCH2), 3.65 (s, br, 2H, NH2), 2.41 (t, J = 6.8 Hz, 2H, 
CH2CO), 1.41 (s, 9H, C(CH3)3); 13C NMR (CDCl3) 173.6 (C=O), 154.3 (NC=O), 141.8 (C-1), 131.1 
(C-4), 129.2 (C-2 & C-6), 114.1 (C-3 & C-5), 79.8 (C(CH3)3), 48.7 (NCH2), 34.2 (CH2CO), 20.3 
(ArCH3); MS (ES): m/z 314.1 (M+H)•+; IR (KBr) 3300s (NH), 3050m (Ar C-H), 1650s (CONH) cm-1. 
 
3-(2-(4-Chlorophenylamino)ethyl)-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-
carboxamide 2g 
General Method C: Preparation of mono-imidazotetrazines 
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Hydrazide 13g (1.0 g, 4.68 mmol) was dissolved in dichloromethane (20 mL). Water (20 mL) was 
added followed by HCl (2.5 mL, 37%). The mixture was cooled in an ice/CaCl2 bath and a solution 
of NaNO2 (0.39 g, 56.2 mmol, 1.2 eq) in water (10 mL) was added with strong agitation at below –5 
°C. The ice bath was removed and dichloromethane (20 mL) was added. The reaction mixture was 
stirred for 40 min and the organic layer was separated, dried over MgSO4 and evaporated to give 
the crude azide 14g as an oil, identified by IR. The oil was diluted with toluene (100 mL) and 
heated under reflux for 1 h under N2. The volatile components were removed to give the crude 
isocyanate 15g as an oil. Diethylether (150 mL) was added and the mixture heated with strong 
agitation. The hot ether solution was decanted leaving an oily residue of impurities behind. The 
ether layer was evaporated to leave pure isocyanate as pale yellow oil (IR νmax 2260s). The 
isocyanate (0.1 g, 0.48 mmol) was mixed with diazo-IC 518 (0.07 g, 0.48 mmol, 1 eq) in dry DMSO 
(0.3 mL) under N2 at RT in the absence of light for 24 h. The reaction was quenched with water (10 
mL) and the resultant solid collected by filtration and washed with copious amounts of water to 
leave imidazotetrazine 2g as a brown solid (0.16 g, 29%): m.p. 160–161 °C; 1H NMR (DMSO-d6, 
600 MHz) 8.84 (s, 1H, imidazole CH), 7.82 & 7.70 (2 × br s, 2H, CONH2), 7.62 (d, J = 8.8 Hz, 2H, 
3-H & 5-H), 7.54 (d, J = 8.8 Hz, 2H, 2-H & 6-H), 4.52 (t, J = 6.0 Hz, 2H, NCH2), 4.42 (t, J = 6.0 Hz, 
2H, CH2CO), 3.3 (br s, NH-aniline & H2O); 13C NMR (DMSO-d6, 151 MHz) 161.8 (C=O amide), 
140.0 (C-1), 139.4 (C=O tetrazine), 134.4 (Cq tetrazine), 132.7 (C-4), 131.8 (Cq imidazole), 130.0 
(C-3 & C-5), 129.5 (C-H imidazole), 122.3 (C-2 & C-6), 45.9 (CH2N-aniline), 42.0 (CH2N-tetrazine); 
MS (ES): m/z 334.1 (M+H)•+; IR (KBr) 3450m & 3300 (CONH2), 1750s (C=O), 1650s (CONH2), 
1600m & 1500s (Ar-H) cm-1. Anal. C20H19N13O4·0.25H2O,  CHN. 
 
3-(2-(Methyl(phenyl)amino)ethyl)-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-
carboxamide 2a 
Prepared according to General Method C. The product was purified by flash column 
chromatography (2% MeOH/CHCl3) and imidazotetrazine 2a was obtained as a white solid (0.34 g, 
21%): m.p. 186–187 °C. 1H NMR (DMSO-d6, 600 MHz) 8.77 (s, 1H, imidazole CH), 7.79 & 7,68 (2 
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× br s, 2H, CONH2), 7.06 (t, J = 8.6 Hz, 2H, 3-H & 5-H), 6.68 (d, J = 8.6 Hz, 2H, 2-H & 6-H), 6.50 (t, 
J = 8.6 Hz, 1H, 4-H), 4.46 (t, J = 6.4 Hz, 2H, NCH2), 3.80 (t, J = 6.4 Hz, 2H, CH2CO), 2.91 (s, 3H, 
NCH3); 13C NMR (DMSO-d6, 151 MHz) 161.9 (CONH2), 148.9 (C-1), 139.6 (C=O tetrazine), 134.7 
(Cq tetrazine), 131.3 (Cq imidazole), 129.4 (C-3 & C-5), 129.2 (C-H imidazole), 116.6 (C-4), 112.4 
(C-2 & C-6), 50.3 (CH2N-aniline), 46.4 (CH2N-tetrazine), 38.3 (CH3); MS (ES): m/z 314.2 (M+H)•+; 
627.4 (2M+H) •+; IR ฀(KBr) 3450m (CONH2), 1750s (C=O), 1675s (CONH2), 1600m (Ar-H) cm-1. 
Anal. C14H15N7O2, CHN. 
 
3-(2-((4-Chlorophenyl)(methyl)amino)ethyl)-4-oxo-3,4-dihydroimidazo[5,1-
d][1,2,3,5]tetrazine-8-carboxamide 2d 
Prepared by General Method C. The product was precipitated with water, collected by filtration 
and the crude solid dried and suspended in chloroform (20 mL). The impurities were removed by 
filtration and the filtrate evaporated to yield imidazotetrazine 2d as a yellow solid (0.084 g, 25%): 
m.p. 154–155 °C 1H NMR (DMSO-d6, 600 MHz) 8.76 (s, 1H, imidazole CH), 7.75 & 7.65 (2 × br s, 
2H, CONH2), 7.07 (d, J = 8.8 Hz, 2H, 3-H & 5-H), 6.66 (d, J = 8.8 Hz, 2H, 2-H & 6-H), 4.43 (t, J = 
6.6 Hz, 2H, CH2N), 3.77 (t, J = 6.6 Hz, 2H, CH2CO), 2.87 (s, 3H, NCH3); 13C NMR (151 MHz, 
DMSO-d6) 161.9 (CONH2), 147.8 (C-1), 139.6 (C=O tetrazine), 134.7 (Cq tetrazine), 131.4 (Cq 
imidazole), 129.2 (C-H imidazole), 129.1 (C-3 & C-5), 120.3 (C-4), 113.9 (C-2 & C-6), 50.4 (CH2N-
aniline), 46.3 (CH2N-tetrazine), 38.5 (CH3); MS (ES): m/z 348.2 (M+H)•+; 695.3 (2M+H)•+; 717.3 
(2M+Na)•+; IR (KBr) 3450m (CONH2), 1750s (C=O), 1675s (CONH2), 1600m & 1500s (Ar-H) cm-1. 
Anal. C14H14ClN7O2·0.5 H2O, CHN. 
 
tert-Butyl 2-(8-carbamoyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazin-3(4H)-yl)ethyl(4-
chlorophenyl) carbamate 2f 
Prepared according to General Method C. The product was purified by flash column 
chromatography (10% AcOH/CHCl3) and imidazotetrazine 2f was obtained as a white solid (0.15 g, 
51%): m.p. 177–178 °C; 1H NMR (DMSO-d6, 600 MHz) 8.91 (s, 1H, imidazole CH), 7.83 & 7.70 (2 
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× br s, 2H, CONH2), 7.40 (d, J = 8.8 Hz, 2H, 3-H & 5-H), 7.32 (d, J = 8.8 Hz, 2H, 2-H & 6-H), 4.40 
(t, J = 6.7 Hz, 2H, NCH2), 4.04 (t, J = 6.5 Hz, 2H, CH2CO), 1.11 (s, 9H, C(CH3)3); 13C NMR (DMSO-
d6, 151 MHz) 161.8 (CONH2), 154.3 (N(CO)O), 140.8 (C-1), 139.6 (CO tetrazine), 134.6 (Cq 
tetrazine), 131.4 (Cq imidazole), 131.0 (C-4), 129.4 (C-H imidazole), 129.2 & 129.1 (C-3 & C-5,C-2 
& C-6), 80.74 (C(CH3)3), 48.3 & 48.0 (CH2N-tetrazine & CH2N-aniline), 28.0 (CH3); MS (ES): m/z 
434.3 (M+H)•+; 456.2 (M + Na)•+; IR (KBr) 3450m (CONH2), 3150m (CONH2), 1750s (C=O), 1700s 
(CONH2), 1600m & 1500s (Ar-H) cm-1. Anal. C18H20ClN7O4·1/3 H2O, CHN. 
 
3-(2-(Methyl(4-methyl-3-nitrophenyl)amino)ethyl)-4-oxo-3,4-dihydroimidazo[5,1-
d][1,2,3,5]tetrazine-8-carboxamide 2h 
Prepared according to General Method C from hydrazide 13b. On completion of the reaction, the 
mixture was quenched with propan-2-ol (10 mL) and the solid collected by filtration and washed 
with propan-2-ol then methanol to leave imidazotetrazine 2h as an orange solid (0.43 g, 24%): m.p. 
133–134 °C. 1H NMR (DMSO-d6, 600 MHz) 8.76 (s, 1H, imidazole CH), 7.77 & 7,66 (2 × br s, 2H, 
CONH2), 7.38 (d, J = 2.0 Hz, 1H, 2-H), 7.20 (d, J = 8.4 Hz, 1H, 5-H), 7.14 (br d, J = 8.4 Hz, 1H, 6-
H), 4.44 (t, J = 6.2 Hz, 2H, CH2N-aniline), 3.45 (t, J = 6.2 Hz, 2H, CH2N-tetrazine), 2.75 (s, 3H, 
NCH3), 2.12 (s, 3H, ArCH3); 13C NMR (DMSO-d6, 151 MHz) 161.9 (CONH2), 143.0 (C-3), 142.5 (C-
1), 139.4 (C=O tetrazine), 134.6 (Cq tetrazine), 134.3 (C-2), 131.4 (Cq imidazole), 131.3 (C-4), 
129.2 (C-H imidazole), 125.3 (C-6), 121.8 (C-5), 53.4 (CH2N-aniline), 46.4 (CH2N-tetrazine), 40.7 
(CH3N), 20.0 (ArCH3); MS (ES): m/z 373.2 (M+H)•+; 395.2 (M + Na)•+. Anal. C15H16N8O4·0.15 H2O, 
CHN. 
 
3-(2-((4-Methoxy-2-nitrophenyl)(methyl)amino)ethyl)-4-oxo-3,4-dihydroimidazo[5,1-
d][1,2,3,5]tetrazine-8-carboxamide 2i 
Prepared according to General Method C from 13e. The product was purified by flash column 
chromatography (10% AcOH/CHCl3). The solid was washed with 50% MeOH/H2O and 
imidazotetrazine 2i was obtained as a purplish red solid (0.21 g, 26%): m.p. 166–168 °C. 1H NMR 
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(DMSO-d6, 600 MHz) 8.80 (s, 1H, imidazole CH), 7.79 & 7.67 (2 × br s, 2H, CONH2), 7.36 (d, J = 
8.9
 
Hz, 1H, 6-H), 7.18 (d, J = 3.0
 
Hz, 1H, 3-H), 7.07 (dd, J = 3.0, 8.9
 
Hz, 1H, 5-H), 4.42 (t, J = 6.0
 
Hz, 2H, CH2N-aniline), 3.68 (s, 3H, OCH3) 3.35 (t, J = 6.0 Hz, 2H, CH2N-tetrazine), 2.70 (s, 3H, 
NCH3); 13C NMR (DMSO-d6, 151 MHz) 162.0 (CONH2, 155.2 (C-4), 145.8 (C-2), 139.4 (C=O 
tetrazine), 138.6 (C-1), 134.7 (Cq tetrazine), 131.3 (Cq imidazole), 129.2 (C-H imidazole), 125.1 
(C-6), 119.9 (C-3), 108.9 (C-5), 56.4 (CH3O), 54.5 (CH2N-aniline), 46.6 (CH2N-tetrazine), 42.0 
(NCH3); MS (ES): m/z 389.2 (M+H)•+; 411.2 (M + Na)•+; IR (KBr) 3425m (CONH2), 3150m 
(CONH2), 1750s (C=O), 1700s (CONH2), 1600m & 1525s (Ar-H) cm-1. Anal. C15H16N8O5·0.1 H2O, 
CHN. 
 
Modified Procedure for tetrazine 2c 
3-(2-(N-(4-Fluorophenyl)-N-methylamino)ethyl)-4-oxo-3H,4H-imidazo[1,5-
d][1,2,3,5]tetrazine-8-carboxamide 2c 
 
3-(N-(4-Fluorophenyl)-N-methylamino)propanoyl azide 14c 
Hydrazide 13c (0.25 g, 1.2 mmol) was dissolved in a mixture of AcOH (0.66M 15 mL) and DCM 
(15 mL), the mixture was then stirred on a CaCl2-ice bath at 0 ºC, a solution of NaNO2 (0.49 g, 7.1 
mmol) in H2O (25 mL) was added dropwise keeping the exothermic reaction at 0–5 ºC. A further 
amount of DCM (20 mL) was added, the DCM layer separated, washed with H2O (20 mL) dried 
over MgSO4, then filtered. Formation of azide 14c was confirmed by IR. 1H NMR (CDCl3, 600 
MHz): 6.93 (t, 2H, JHH = 3JHF = 9.1 Hz, 3',5'-H), 6.66 (dd, 2H, JHH = 9.1 Hz, 4JHF = 4.3 Hz, 2',6'-H), 
3.60 (t, 2H, J = 7.1 Hz, 3-H), 2.86 (s, 3H, NCH3), 2.55 (t, 2H, J = 7.1 Hz, 2-H); 13C NMR (CDCl3, 
151 MHz) 179.2 (C-1), 155.3 (d, 1JCF = 237 Hz, C-4'), 145.2 (C-1'), 115.8 (d, 2JCF = 21.7 Hz, C-
3',5'), 114.3 (d, 3JCF = 7.2 Hz, C-2',6'), 49.4 (C-3), 38.9 (NCH3), 34.2 (C-2); IR (liq. film) 2914w (CH 
st), 2137s (CON3), 1711s (CO), 1511m (C=C), 815s (p-di-substituted aromatic ring) cm-1. 
 
2-(N-(4-Fluorophenyl)-N-methylamino)ethyl isocyanate 15c  
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The anhydrous DCM solution of azide 14c was stirred under nitrogen at RT overnight. 
Isocyanate 15c formation was confirmed by IR and 1H NMR. The DCM was evaporated under 
reduced pressure at low temperature (an ice bath was used to lower the temperature). The 
isocyanate was collected as a yellow oil (0.2 g, 77%). 1H NMR (CDCl3, 600 MHz) 6.95 (t, 2H, JHH = 
3JHF = 9.1 Hz, 3',5'-H), 6.69 (dd, 2H, JHH = 9.1 Hz, 4JHF = 4.3 Hz, 2',6'-H), 3.43 (m, 4H, 1,2-H), 2.94 
(s, 3H, NCH3); 13C NMR (CDCl3, 151 MHz) 157.2 (NCO), 155.3 (d, 1JCF = 237 Hz, C-4'), 145.2 (C-
1'), 115.8 (d, 2JCF = 21.7 Hz, C-3',5'), 114.4 (d, 3JCF = 7.2 Hz, C-2',6'), 54.5 (C-3), 40.9 (C-2), 39.6 
(NCH3); IR (liq film) 3057w (Ar-CH st), 2917w (CH st), 2270s (NCO), 1512m (C=C), 1228m, 816s 
(p-di-substituted aromatic ring) cm-1; MS (ES) m/z 195 (100%) (M+H)+. 
 
3-(2-(N-(4-Fluorophenyl)-N-methylamino)ethyl)-4-oxo-3H,4H-imidazo[1,5-
d][1,2,3,5]tetrazine-8-carboxamide 2c 
Isocyanate 15c (0.2 g, 1.03 mmol) was diluted with DMSO (1.5 mL) under nitrogen then added 
to a suspension of diazo-IC 5 (0.14 g, 1.03 mmol) in DMSO (1.5 mL), the mixture was stirred at rt 
protected from light for 48 h. The 1H NMR spectrum showed product 2c formation. The reaction 
mixture was suspended in H2O (30 mL) and filtered, the residue was washed with copious 
amounts of H2O until the washings came through colorless and then washed with Et2O. The solid 
was purified by flash column chromatography, 10% AcOH in CHCl3 was used for the elution; the 
fractions containing the product were evaporated to give an orange solid. The solid was then re-
dissolved in CHCl3 and filtered, the CHCl3 evaporated and the residue re-suspended in Et2O and 
then collected by filtration to give 2c (0.057 g, 17%), m.p. 172–173 ºC . 1H NMR (DMSO-d6, 600 
MHz): 8.77 (s, 1H, 6-H), 7.75 & 7.65 (2 × br s, 2H, CONH2), 6.91 (t, 2H, JHH = JHF = 9.1 Hz, 3',5'-H), 
6.69 (dd, 2H, JHH = 9.1 Hz, JHF = 4.3 Hz, 2',6'-H), 3.45 (t, 2H, J = 6.4 Hz, 1-H), 3.77 (t, 2H, J = 6.4 
Hz, 2-H), 2.90 (s, 3H, NCH3); 13C NMR (CDCl3, 151 MHz) 161.89 (CONH2), 155.0 (d, 1JCF = 235.5 
Hz, C-4'), 145.9 (C-1'), 139.5 (C-4), 134.7 (C-8a), 131.3 (C-8), 129.2 (C-6), 115.7 (d, 2JCF = 21.7 
Hz, C-3',5'), 113.6 (d, 3JCF = 7.2 Hz, C-2',6'), 50.9 (C-2), 46.3 (C-1) 38.7 (NCH3); IR (KBr) 3439s 
(NH), 3117m (Ar-CH st), 2914w (CH st), 1749s (C(4)O), 1682s (CONH2), 1515 s, 1458m (C=C), 
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820m (p-di-substituted aromatic ring) cm-1; MS (ES): m/z 331.9 (20%) (M+H)+, 353.9 (10%) 
(M+Na)+, 195.0 (100%) (C10H11FN2O+H)+. Anal. C14H14FN7O2·0.75H2O, CHN. 
 
Modified Procedure for tetrazine 2e 
 
3-(N-Methyl-N-(4-nitrophenyl)amino)propanoyl azide 14e and 
3(N-methyl-N-(2-nitrophenyl)amino)propanoyl azide  
Hydrazide 13a (0.3g, 1.6 mmol) was dissolved in a mixture of DCM (10 mL) and HCl (10 mL, 
14.8%), the solution was stirred at 0 ºC on a CaCl2-ice bath, NaNO2 (0.66 g, 9.6 mmol) solution in 
H2O (10 mL) was added gradually, keeping the exothermic reaction between 0–5 ºC. A further 
portion of DCM (15 mL) was added, the DCM layer was separated, washed with two portions of 
H2O (20 mL) dried over MgSO4, then filtered. Formation of the azide 14e was confirmed by IR and 
1H NMR which also showed the formation of small amount of the ortho-nitrated azide in ratio 1:5. 
Azide 14e 1H NMR (CDCl3, 600 MHz) 8.12 (½AB, 2H, J = 9.5 Hz, 3',5'-H), 6.61 (½AB, 2H, J = 9.5 
Hz, 2',6'-H), 3.77 (t, 2H, J = 7.0 Hz, 3-H), 3.10 (s, 3H, NCH3) 2.62 (t, 2H, J = 7.0 Hz, 2-H); 13C NMR 
(CDCl3) δ: 178.5 (CON3), 152.8 (C-4'), 133.2 (C-1'), 126.4 (C-3',5'), 110.6 (C-2',6'), 48.0 (C-3), 
39.1 (NCH3), 34.4 (C-2); IR (liq film) 2918w (CH st), 2140s (N3), 1711s (CO), 1597s (NO2 st as), 
1518 s (C=C), 1311s (NO2 st) cm-1. o-NO2-Azide: 1H NMR (CDCl3, 600 MHz): 7.72 (d, 1H, J = 8.9 
Hz, 5'-H), 7.42 (t, 1H, J = 8.9 Hz, 4'-H), 7.21 (d, 1H, , J = 8.9 Hz, 2'-H ), 6.96 (t, 1H, J = 8.9 Hz, 3'-
H), 3.46 (t, 2H, J = 7.1 Hz, 3-H), 2.80 (s, 3H, NCH3) 2.62 (t, 2H, J = 7.1 Hz, 2-H). 
 
2-[(4-Nitrophenyl)methylamino]ethylisocyanate 15e 
The anhydrous DCM solution of the crude azide 14e was stirred under nitrogen at RT overnight. 
Isocyanate formation was confirmed by IR. The DCM was evaporated under reduced pressure at 
low temperature (an ice bath was used to lower the temperature) and the crude isocyanate 15e 
collected as a yellow oil (0.27 g, 90 %). 1H NMR (CDCl3, 600 MHz) 8.15 (½AB, 2H, J = 9.4 Hz, 
3',5'-H), 6.67 (½AB, 2H, J = 9.4 Hz, 2',6'-H), 3.66 (t, 2H, J = 6.2 Hz, 2-H), 3.57 (t, 2H, J = 6.2 Hz, 1-
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H), 3.15 (s, 3H, NCH3); 13C NMR (CDCl3, 151 MHz)153.1 (NCO), 145.2 (C-4'), 138.1 (C-1'), 126.4 
(C-3',5'), 110.7 (C-2',6'), 52.6 (C-2), 40.7 (C-1) , 39.5 (NCH3); IR (liq film) 2919w (CH st), 2270s 
(NCO), 1597s (NO2 st as), 1517 s (C=C), 1311s (NO2 st) cm-1. Isocyanate ortho-nitro isomer: 1H 
NMR (CDCl3, 600 MHz) 7.74 (d, 1H, J = 8.4 Hz, 5'-H), 7.45 (t, 1H, , J = 8.4 Hz, 4'-H), 7.18 (d, 1H, , 
J = 8.4 Hz, 2'-H ), 6.99 (t, 1H, J = 8.9 Hz, 3'-H), 3.48 (t, 2H, J = 6.0 Hz, 3-H), 2.90 (s, 3H, NCH3), 
3.31 (t, 2H, J = 7.1 Hz, 2-H). 
 
3-(2-N-Methyl-N-(4-nitrophenyl)-N-methylamino)ethyl)-4-oxo-3H,4H-imidazo[1,5-
d][1,2,3,5]tetrazine-8-carboxamide 2e and 
3-(2-(N-methyl-N-(2-nitrophenyl)-N-methylamino)ethyl)-4-oxo-3H,4H-
imidazo[5,1d][1,2,3,5]tetrazine-8-carboxamide  
The crude mixture of the isocyanate 15e (0.27 g, 1.22 mmol) was diluted with DMSO (1.5 mL) 
under N2 then added to a suspension of diazo-IC 5 (0.17 g, 1.22 mmol) in DMSO (1.5 mL), the 
mixture was stirred at RT protected from light for 48 h. The reaction mixture was then suspended in 
water (30 mL) and filtered. The solid on the filter was washed with copious amounts of H2O until 
the washings came through colorless, then with Et2O. The dry solid was purified by flash column 
chromatography eluted with a gradient 5–20% AcOH in CHCl3. 1H NMR showed impurities from 
silica, so the imidazotetrazinone solid was dissolved in DMF, filtered and the imidazotetrazinone 
precipitated as a yellow solid by H2O addition. The solid was collected by filtration, washed with 
copious amounts of water and then dried to give 2e (0.025g, 6 %), m.p. 179–180 ºC. 1H NMR 
(DMSO-d6, 600 MHz)8.81 (s, 1H, 6-H), 8.00 (½AB, 2H, J = 9.2 Hz, 3',5'-H), 7.77 & 7.67 (2 × br s, 
2H, CONH2), 6.82 (½AB, 2H, J = 9.2 Hz, 2',6'-H), 4.52 (t, 2H, J = 6.3 Hz, 1-H), 3.96 (t, 2H, J = 6.3 
Hz, 2-H), 3.07 (s, 3H, NCH3); 13C NMR (DMSO-d6, 151 MHz) 161.9 (CONH2), 154.0 (C-4'), 139.7 
(C-4), 136.6 (C-1'), 134.7 (C-8a), 131.6 (C-8), 129.5 (C-6), 126.3 (C-3',5'), 111.4 (C-2',6'), 50.3 (C-
2), 46.4 (C-1) 39.2 (NCH3); IR (KBr) 3443m (NH), 2919w (CH st), 1749s (C(4)O), 1684s (CONH), 
1597s (NO2 st as), 1457m (C=C), 1316s (NO2 st) cm-1; MS(ES): m/z 359.1(80%) (M+H)+, 
381.1(100%) (M+Na)+; Anal. C14H14N8O4 ·0.6 AcOH·0.2 CHCl3, CHN. 
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meta-NO2 isomer: 1H NMR (DMSO-d6, 600 MHz) 8.83 (s, 1H, 6-H), 7.83 & 7.71 (2 × br s, 2H, 
CONH2), 7.65 (d, 1H, J = 9.1 Hz, 5'-H), 7.46 (t, 1H, J = 9.1 Hz, 4'-H), 7.31 (t, 1H, J = 9.1 Hz, 2'-H), 
6.92 (d, 1H, J = 9.1 Hz, 3'-H), 4.52 (t, 2H, J = 6.1 Hz, 1-H), 3.59 (t, 2H, J = 6.1 Hz, 2-H), 2.83 (s, 
3H, NCH3). 
 
Dimethyl 3,3'-(4-chlorophenylazanediyl)dipropanoate 8d36 
General Method D: Double Conjugate addition to anilines. 
4-Chloroaniline (10 g, 78.4 mmol) was mixed with methyl acrylate (67.5 g, 784 mmol, 10 eq), 
cuprous chloride (1.24 g, 12.5 mmol, 0.16 eq) and AcOH (100 mL) and heated under reflux at 140 
°C for 48 h. The reaction mixture was allowed to reach RT and water (300 mL) was added with 
strong agitation. The batch was allowed to stand in the fridge overnight and the water layer was 
decanted leaving the oil behind. The oil was washed with more water (2 × 300 mL), diluted with 
diethylether (200 mL), washed with water (300 mL), dried over MgSO4 and evaporated to give 
diester 8d as a light brown oil (19.0 g, 88%). 1H NMR (CDCl3) 7.17 (d, J = 8.8 Hz, 2H, 3-H & 5-H), 
6.68 (d, J = 8.8
 
Hz, 2H, 2-H & 6-H), 3.65 (s, 6H, 2 x CH3), 3.61 (t, J = 7.2 Hz, 4H, 2 x CH2N), 2.57 
(t, J = 7.2
 
Hz, 4H, 2 x CH2CO); 13C NMR (CDCl3) 172.3 (C=O), 145.0 (C-1), 129.4 (C-3 & C-5), 
129.3 (C-4), 114.1 (C-2 & C-6), 51.9 (CH3), 47.2 (NCH2), 32.1 (CH2CO); MS (ES): m/z 300.1 
(M+H)•+; IR ฀(film) 1725s  (C=O), 1175m (C-O) c -1. 
 
Dimethyl 3,3'-(phenylazanediyl)dipropanoate 8a37 
Prepared according to General method D. Diester 8a was obtained as an orange oil (18.8 g, 
67%). 1H NMR (CDCl3) 7.16 (m, 2H, 3-H & 5-H), 6.62 (m, 3H, 2-H, 4-H, 6-H), 3.60 (m, 10H, 2 x 
CH2N-aniline & 2 x OCH3), 2.52 (t, J = 7.1 Hz, 4H, 2 x CH2CO); 13C NMR (CDCl3) 172.6 (C=O), 
146.7 (C-1), 129.6 (C-3 & C-5), 117.2 (C-4), 112.6 (C-2 & C-6), 51.8 (CH3), 47.0 (NCH2), 32.3 
(CH2CO); MS (ES): m/z 266.1 (M+H)•+; IR ฀ (film) 1725s  (C=O), 1175  (C-O) cm-1. 
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Dimethyl 3,3'-(4-fluorophenylazanediyl)dipropanoate 8c37 Prepared according to General 
Method D. Diester 8c was obtained as a yellow oil (0.99 g, 75%). 1H NMR (CDCl3) 6.92 (m, 2H, 3-
H & 5-H), 6.74 (m, 2H, m, 2-H & 6-H), 3.64 (s, 6H, 2 x CH3), 3.56 (t, J = 7.2 Hz, 4H, 2 x CH2N), 
2.52 (t, J = 7.2 Hz, 4H, 2 x CH2CO); 13C NMR (CDCl3) 172.6 (C=O), 156.0 (d, 1JCF = 237 Hz, C-4), 
143.5 (C-1), 115.9 (d, 2JCF = 22 Hz, C-3 & C-5), 114.9 (d, 3JCF = 7 Hz, C-2 & C-6), 51.8 (CH3), 47.7 
(CH2N), 32.3 (CH2CO); 19F NMR (CDCl3) –127.62; MS (ES): m/z 284.0 (M+H)•+; IR ฀ (KBr) 3025m
(Ar C-H), 2950m (C-H), 1725s (C=O), 1525m (Ar C=C), 1175m (C-O), cm-1. 
 
Dimethyl 3,3'-(4-methoxyphenylazanediyl)dipropanoate 8e37 
Prepared according to General Method D. Diester 8e was obtained as an orange oil (21.7 g, 
90%). 1H NMR (CDCl3) 6.84 (d, 2H, J = 8.1 Hz, 3-H & 5-H), 6.74 (d, 2H, J = 8.1 Hz, 2-H & 6-H), 
3.75 (s, 3H, CH3), 3.64 (s, 6H, 2 x CH3), 3.53 (t, J = 7.1 Hz, 4H, 2 x NCH2), 2.51 (t, J = 7.1 Hz, 4H, 
2 x CH2CO); 13C NMR (CDCl3) 175.4 (C=O), 152.9 (C-4), 141.0 (C-1), 121.4 (C-3 & C-5), 114.9 (C-
2 & C-6), 55.8 (CH3), 51.9 (CH3), 50.5 (NCH2), 33.5 (CH2CO); MS (ES): m/z 296.1 (M+H)•+; IR ฀ 
(film) 1725s (C=O), 1175m (C-O) cm-1. 
 
3,3'-(4-Chlorophenylazanediyl)dipropanehydrazide 10d 
 
General Method E: Preparation of bis-hydrazides 
Diester 8d (19 g, 63.4 mmol) was mixed with hydrazine hydrate (12.6 g, 0.25 mol, 4 eq) in 
propan-2-ol (60 mL) for 48 h at RT. The resulting solid was collected by filtration, washed with 
propan-2-ol and dried in vacuo to give hydrazide 10d as white solid (18.8 g, 99%): 1H NMR 
(DMSO-d6) 9.03 (s, 2H, 2 x NH), 7.15 (d, 2H, J = 9.1 Hz, 3-H & 5-H), 6.66 (d, 2H, J = 9.1 Hz, 2-H & 
6-H), 4.18 (br s, 4H, 2 x NH2), 3.46 (t, J = 7.2 Hz, 4H, 2 x NCH2), 2.23 (t, J = 7.2 Hz, 4H, 2 x 
CH2CO); 13C NMR (DMSO-d6) 170.4 (C=O), 146.4 (C-1), 129.3 (C-3 & C-5), 119.8 (C-4), 113.8 (C-
2 & C-6), 47.4 (NCH2), 31.9 (CH2CO); MS (ES): m/z 300.1 (M+H)•+; IR ฀ (KBr) 3300
(Ar C-H), 1650s (CONH) cm-1. 
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3,3'-(Phenylazanediyl)dipropanehydrazide 10a38 
Prepared according to General Method E. Hydrazide 10a was obtained as a white solid (6.3 g, 
72%). 1H NMR (DMSO) 9.04 (s, 2H, 2 x NH), 7.15 (t, 2H, J = 7.4
 
Hz, 3-H & 5-H), 6.66 (d, 2H, J = 
7.4
 
Hz, 2-H & 6-H), 6.58(t, 2H, J = 7.4
 
Hz, 4-H), 4.18 (br s, 4H, 2 x NH2), 3.48 (t, J = 7.2 Hz, 4H, 2 x 
CH2N), 2.25 (t, J = 7.2 Hz, 4H, 2 x CH2CO); 13C NMR (DMSO) 170.5 (C=O), 147.6 (C-1), 129.7 (C-
3 & C-5), 116.2 (C-4), 112.4 (C-2 & C-6), 47.4 (NCH2), 32.1 (CH2CO); MS (ES): m/z 266.1 (M+H)•+; 
IR ฀ (KBr) 3300s  (NH), 3050m (Ar C-H), 1650s (CONH) cm-1. 
 
3,3'-(4-Fluorophenylazanediyl)dipropanehydrazide 10c 
Prepared according to General Method E. Hydrazide 10c was obtained as a white solid (0.63 g, 
64%): m.p. 131.4 °C. 1H NMR (DMSO-d6) 8.91 (br s, 2H, 2 x NH), 6.88 (m, 2H, 3-H & 5-H), 6.56 
(m, 2H, 2-H & 6-H), 4.07 (br s, 4H, 2 x NH2), 3.33 (t, J = 7.2 Hz, 4H, 2 x CH2N), 2.11 (t, J = 7.2 Hz, 
4H, 2 x CH2CO); 13C NMR (DMSO-d6) 170.5 (C=O), 154.8 (d, 1JCF = 228 Hz, C-4), 144.5 (C-1), 
116.0 (d, 2JCF = 22 Hz, C-3 & C-5), 113.7 (d, 3JCF = 7 Hz, C-2 & C-6), 47.8 (CH2N), 31.9 (CH2CO); 
19F NMR (CDCl3) –129.53; MS (EI): m/z 283.0 (M+H)•+; νmax (KBr) 3300m (NH), 3050m (Ar C-H), 
1650s (CONH), 1525m (Ar C=C) cm-1 
 
3,3'-(4-Methoxyphenylazanediyl)dipropanehydrazide 10e 
Prepared according to General Method E. Hydrazide 10e was obtained as a white solid (20.5 g, 
95%): 1H NMR (CDCl3) 7.39 (br s, 2H, 2 x NH), 6.85 (d, 2H, J = 8.1 Hz, 3-H & 5-H), 6.80 (d, 2H, J 
= 8.1 Hz, 2-H & 6-H), 4.10 (br s, 4H, 2 x NH2), 3.75 (s, 3H, CH3), 3.32 (t, J = 7.1 Hz, 4H, 2 x CH2N), 
2.28 (t, J = 7.1 Hz, 4H, 2 x CH2CO); 13C NMR (CDCl3) 173.4 (C=O), 155.0 (C-4), 142.4 (C-1), 
121.4 (C-3 & C-5), 114.7 (C-2 & C-6), 55.6 (CH3), 50.7 (NCH2), 33.3 (CH2CO); MS (ES): m/z 296.1 
(M+H)•+; νmax (KBr) 3300s (NH), 3050m (Ar C-H), 1650s (CONH) cm-1. 
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3,3'-(2,2'-(4-Chlorophenylazanediyl)bis(ethane-2,1-diyl))bis-(4-oxo-3,4-dihydroimidazo[5,1-
d][1,2,3,5]tetrazine-8-carboxamide) 3d 
General Method F: Preparation of bis-imidazotetrazines 
Hydrazide 10d (1.0 g, 3.18 mmol, 1 eq) was dissolved in dichloromethane (10 mL). Water (10 
mL) was added followed by HCl (2.5 mL, 37 %). The mixture was cooled in an ice/CaCl2 bath and 
a solution of NaNO2 (0.57 g, 8.26 mmol, 2.6 eq) in water (10 mL) was added with strong agitation 
below 5 °C. After the addition, the reaction was allowed to reach RT and stirred overnight. The 
organic layer was separated, dried over MgSO4 and evaporated to give the azide 11d as a crude 
oil, identified by IR. The oil was diluted with toluene (100 mL) and heated under reflux for 2 h under 
N2. The volatile components were removed to give the crude isocyanate 9d as an oil. Diethylether 
(150 mL) was added and the mixture heated with strong agitation. The hot solution was decanted 
leaving a residue of oily impurities behind. The ether was evaporated to leave pure isocyanate as 
pale yellow oil (IR νmax 2260s). The isocyanate (0.29g, 1.03 mmol) was mixed with diazo-IC 5 (0.3 
g, 2.17 mmol, 2.1 eq) in dry DMSO (0.1 mL) under N2 at RT in the absence of light for 24 h. The 
bis-imidazotetrazine was purified by flash column chromatography eluting with CHCl3:AcOH (1:1) 
to give imidazotetrazine 3d as a light brown solid (0.1 g, 6%): m.p. 143-144 °C. 1H NMR (DMSO-
d6, 600 MHz) 8.79 (s, 2H, imidazole CH), 7.77 & 7.66 (2 × br s, 4H, 2 × CONH2), 7.09 (d, J = 8.9 
Hz, 2H, 3-H & 5-H), 6.80 (d, J = 8.9 Hz, 2H, 2-H & 6-H), 4.42 (t, J = 6.6 Hz, 4H, 2 x NCH2 aniline), 
3.78 (t, J = 6.6 Hz, 4H, 2 x CH2N-tetrazine); 13C NMR (DMSO-d6, 151 MHz) 161.9 (C=O amide), 
146.2 (C-1), 140.0 (C=O tetrazine), 134.7 (Cq tetrazine), 131.4 (Cq imidazole), 2 x 129.3 (C-3 & C-
5, C-H imidazole), 120.9 (C-4), 114.2 (C-2 & C-6), 49.1 (CH2N-aniline), 46.4 (CH2N-tetrazine); MS 
(ES): m/z 540.2 (M+H)•+; 562.3 (M + Na)•+; IR (KBr) 3450m (CONH2), 1750s (C=O), 1675s 
(CONH2), 1600m & 1500s (Ar-H) cm-1. Anal. C20H18ClN13O4·0.85 AcOH, CHN. 
 
3,3'-(2,2'-(Phenylazanediyl)bis(ethane-2,1-diyl))bis-(4-oxo-3,4-dihydroimidazo[5,1-
d][1,2,3,5]tetrazine-8-carboxamide) 3a 
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Prepared according to General Method F. The product was purified by flash column 
chromatography (5% AcOH/CH3CN) and imidazotetrazine 3a was obtained as a yellow solid (0.38 
g, 60%): m.p. 194–195 °C; 1H NMR (DMSO-d6, 600 MHz) 8.79 (s, 2H, imidazole CH), 7.77 & 7.66 
(2 × br s, 4H, 2 × CONH2), 7.06 (t, J = 7.5 Hz, 2H, 3-H & 5-H), 6.80 (d, J = 7.5 Hz, 2H, 2-H & 6-H), 
6.51 (t, J = 7.5
 
Hz, 1H, 4-H), 4.44 (t, J = 6.9 Hz, 4H, 2 x CH2N-aniline), 3.79 (t, J = 6.9 Hz, 4H, 2 x 
CH2N-tetrazine); 13C NMR (DMSO-d6, 151 MHz) 161.9 (C=O amide), 147.2 (C-1), 139.7 (C=O 
tetrazine), 134.7 (Cq tetrazine), 131.3 (Cq imidazole), 129.6 & 129.3 (C-3 & C-5, C-H imidazole), 
117.1 (C-4), 112.5 (C-2 & C-6), 48.8 (CH2N-aniline), 46.6 (CH2N-tetrazine); MS (ES): m/z 506.3 
(M+H)•+; νmax (KBr) 3450m & 3150m (CONH2), 1740s (C=O), 1675s (CONH2), 1600m & 1510s (Ar-
H) cm-1. Anal. C20H19N13O4 ·H2O·0.8AcOH, CHN. 
 
3,3'-(2,2'-(4-Fuorophenylazanediyl)bis(ethane-2,1-diyl))bis-(4-oxo-3,4-dihydroimidazo[5,1-
d][1,2,3,5]tetrazine-8-carboxamide) 3c 
Prepared according to General Method F. Imidazotetrazine 3c was obtained as dark yellow solid 
(0.04 g, 42%): m.p. 290–291 °C; 1H NMR (DMSO-d6, 600 MHz) 8.78 (s, 2H, imidazole CH), 7.77 & 
7.66 (2 × br s, 4H, 2 × CONH2), 6.91 (m, 2H, 3-H & 5-H), 6.80 (m, 2H, 2-H & 6-H), 4.41 (t, J = 6.7 
Hz, 4H, 2 x CH2N-aniline), 3.76 (t, J = 6.7 Hz, 4H, 2 x CH2N-tetrazine); 13C NMR (DMSO-d6, 151 
MHz) 161.9 (C=O amide), 155.0 (d, 1JCF = 243 Hz, C-4), 144.1 (C-1), 139.7 (C=O tetrazine), 134.7 
(Cq tetrazine), 131.3 (Cq imidazole), 129.3 (C-H imidazole), 116.0 (d, 2JCF = 23.1 Hz, C-3 & C-5), 
114.1 (d, 3JCF = 7.2 Hz, C-2 & C-6), 49.4 (CH2N-aniline), 46.5 (CH2N-tetrazine); MS (ES): m/z 524.3 
(M+H)•+; 546.2 (M + Na) •+;  IR (KBr) 3450m (CONH2), 1725s (C=O), 1675s (CONH2), 1600m & 
1510s (Ar-H) cm-1. Anal. C20H18FN13O4·0.35 H2O·0.3 AcOH requires, CHN. 
 
3,3'-(2,2'-(4-Methoxy-2-nitrophenylazanediyl)bis(ethane-2,1-diyl))bis-(4-oxo-3,4-
dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide) 3f 
Prepared according to General Method F. The product was purified by flash column 
chromatography (5% AcOH/CH3CN) and imidazotetrazine 3f was obtained as an orange/yellow 
 - 39 - 
 
solid (0.21 g, 26%): m.p. 139–140 °C. 1H NMR (DMSO-d6, 600 MHz) 8.72 (s, 2H, imidazole CH), 
7.77 & 7.67 (2 × br s, 4H, 2 × CONH2), 7.49 (d, J = 9.2 Hz, 1H, 6-H), 7.16 (d, J = 3.0 Hz, 1H, 3-H), 
7.04 (dd, J = 9.2, 3.0
 
Hz, 1H, 5-H), 4.32 (t, J = 6.2 Hz, 4H, 2 x CH2N-aniline), 3.67 (s, 3H, OCH3), 
3.47 (t, J = 6.2 Hz, 4H, 2 x CH2N-tetrazine); 13C NMR (DMSO-d6, 151 MHz) 161.9 (C=O amide), 
156.3 (C-4), 147.8 (C-2), 139.5 (C=O tetrazine), 135.6 (C-1), 134.8 (Cq tetrazine), 131.3 (Cq 
imidazole), 129.1 (C-H imidazole), 126.9 (C-5), 119.4 (C-6), 109.1 (C-3), 56.4 (CH3O), 52.1 (CH2N-
aniline), 46.9 (CH2N-tetrazine); MS (ES): m/z 581.3 (M+H)•+; 603.1 (M + Na)•+; IR (KBr) 3450m 
(CONH2), 1750s (C=O), 1675s (CONH2), 1600m & 1525s (Ar-H) cm-1. Anal. C21H20N14O7·1.4 
H2O·0.4 AcOH, CHN. 
 
3,3'-(2,2'-(4-Methoxyphenylazanediyl)bis(ethane-2,1-diyl))bis-(4-oxo-3,4-
dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide) 3e 
Prepared by a variation on General Method F using AcOH (0.17 M) in place of HCl. The product 
was purified by flash column chromatography (10% AcOH/CHCl3) and 3e was obtained as red 
solid (0.2 g, 11%): m.p. 178-179 °C. 1H NMR (DMSO-d6, 600 MHz) 8.75 (s, 2H, imidazole CH), 
7.76 & 7,65 (2 × br s, 4H, 2 × CONH2), 6.73 (d, J = 8.1 Hz, 2H, 3-H & 5-H), 6.62 (d, J = 8.1 Hz, 2H, 
2-H & 6-H), 4.39 (t, J = 6.6 Hz, 4H, 2 x CH2N-aniline), 3.72 (t, J = 6.6 Hz, 4H, 2 x CH2N-tetrazine), 
3.53(s, 3H, CH3); 13C NMR (DMSO-d6, 151 MHz) 162.0 (C=O amide), 152.0 (C-4), 141.5 (C-1), 
139.6 (C=O tetrazine), 134.7 (Cq tetrazine), 131.2 (Cq imidazole), 129.2 (C-H imidazole), 115.2 & 
114.9 (C-2 & C-6, C-3 & C-5), 55.6 (CH3), 49.6 (CH2N-aniline), 46.9 (CH2N-tetrazine); MS (ES): 
m/z 536.3 (M+H)•+; 558.3 (M + Na)•+;  IR (KBr) 3450m (CONH2), 1750s (C=O), 1675s (CONH2), 
1600m & 1500s (Ar-H) cm-1. Anal. C21H21N13O5, CHN. 
 
In vitro Chemosensitivty 
Cells used were A2780 (human ovarian carcinoma, from European Collection of Cell Cultures), 
the MMR-deficient derivative A2780-Cp70 (gift of Professor G Margisson, University of 
Manchester, UK). Isogenic HCT116 p53+/+ and HCT116 p53–/– came from Bert Vogelstein.39 Cells 
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were plated into 96-well culture plates at 1 x 103 cells per well and incubated over night at 37 °C in 
a CO2 enriched (5%) atmosphere to enable cells to adhere to the plate. Culture medium was 
removed and replaced with fresh medium containing test compound at concentrations ranging from 
0 (controls) to 250 µM. Following 5 days incubation at 37 °C, cell survival was determined using the 
MTT assay. All TMZ-related compounds were dissolved in DMSO, and the final concentration of 
DMSO in the culture plates was <0.1% (v/v). PaTrin2 was used as an inhibitor of MGMT and cells 
were incubated with test compounds in the presence or absence of 10 µM PaTrin2  
 
 
 
NCI Data Handling 
Standard COMPARE and matrix COMPARE were run using the NCI database Data Build Date: 
2012-04-28. GI50 data were selected and where multiple datasets were available, those averaged 
from the larger number of individual experiments were used. 
 
 
Supporting Information Available: including tabulated IC50 data and statistical analysis for Figures 1 
and 2; NCI mean graphs and COMPARE results for compounds 2d, 3c–e; HPLC analysis of new 
tetrazines 2, 3. This material is available free of charge via the Internet at http://pubs.acs.org. 
 
Abbreviations Used. ATM, ataxia telangiectasia mutated serine/threonine protein kinase; ATR, 
ataxia telangiectasia and Rad3-related protein; BCNU, 1,3-bis(2-chloroethyl)-1-nitrosourea; CCNU, N-
(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea; CHB, chlorambucil; CP, cisplatin; DTIC, 5-(3,3-dimethyl-
1-triazeno)imidazole-4-carboxamide; FANC, Fanconi’s anemia; GBM, glioblastoma multiforme; MEL, 
melphalan; MGMT, O6-Methylguanine-DNA-methyltransferase; MMR, DNA Mismatch repair; 6MP, 6-
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mercaptopurine; MTIC, 5-(3-methyl-1-triazeno)imidazole-4-carboxamide; MTZ, mitozolomide; QSAR, 
quantitative structure-activity relationship; 6TG, 6-thioguanione; TMZ, temozolomide. 
 
*To whom correspondence should be addressed. Phone: +44 (0) 1274 234710. 
Email: r.t.wheelhouse@brad.ac.uk.  
§Present address: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of 
Khartoum, Sudan. 
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